Tenhunen M - Search Results

1

The effect of three dimensional activity distribution on the dose planning of radioimmunotherapy for patients with advanced intraperitoneal pseudomyxoma.

Laitinen JO, Kairemo KJ, Jekunen AP, Korppi-Tommola T, Tenhunen M. Laitinen JO, et al. Among authors: tenhunen m. Cancer. 1997 Dec 15;80(12 Suppl):2545-52. doi: 10.1002/(sici)1097-0142(19971215)80:12+<2545::aid-cncr29>3.3.co;2-t. Cancer. 1997. PMID: 9406708

2

Absorbed dose estimates for 131I-labelled monoclonal antibody therapy in patients with intraperitoneal pseudomyxoma.

Laitinen JO, Tenhunen M, Kairemo KJ. Laitinen JO, et al. Among authors: tenhunen m. Nucl Med Commun. 2000 Apr;21(4):355-60. doi: 10.1097/00006231-200004000-00010. Nucl Med Commun. 2000. PMID: 10845224

3

The use of TL detectors in dosimetry of systemic radiation therapy.

Aschan AC, Toivonen MJ, Lampinen JS, Tenhunen M, Kairemo KJ, Korppi-Tommola ET, Jekunen AP, Sipilä P, Savolainen SE. Aschan AC, et al. Among authors: tenhunen m. Acta Oncol. 1999;38(2):189-96. doi: 10.1080/028418699431609. Acta Oncol. 1999. PMID: 10227440

4

Oligoradionuclidetherapy using radiolabelled antisense oligodeoxynucleotide phosphorothioates.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Anticancer Drug Des. 1996 Sep;11(6):439-49. Anticancer Drug Des. 1996. PMID: 8836109

5

Gene therapy using antisense oligodeoxynucleotides labeled with Auger-emitting radionuclides.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Cancer Gene Ther. 1998 Nov-Dec;5(6):408-12. Cancer Gene Ther. 1998. PMID: 9917096

6

Subclinical cardiotoxicity following adjuvant dose-escalated FEC, high-dose chemotherapy, or CMF in breast cancer.

Erselcan T, Kairemo KJ, Wiklund TA, Hernberg M, Blomqvist CP, Tenhunen M, Bergh J, Joensuu H. Erselcan T, et al. Among authors: tenhunen m. Br J Cancer. 2000 Feb;82(4):777-81. doi: 10.1054/bjoc.1999.0998. Br J Cancer. 2000. PMID: 10732745 Free PMC article. Clinical Trial.

7

Dosimetry of radionuclide therapy using radiophosphonated antisense oligodeoxynucleotide phosphorothioates based on animal pharmacokinetic and tissue distribution data.

Kairemo KJ, Tenhunen M, Jekunen AP. Kairemo KJ, et al. Among authors: tenhunen m. Antisense Nucleic Acid Drug Dev. 1996 Fall;6(3):215-20. doi: 10.1089/oli.1.1996.6.215. Antisense Nucleic Acid Drug Dev. 1996. PMID: 8915506

8

Dosimetry and optimization of in vivo targeting with radiolabeled antisense oligodeoxynucleotides: oligonucleotide radiotherapy.

Kairemo KJ, Jekunen AP, Tenhunen M. Kairemo KJ, et al. Among authors: tenhunen m. Methods Enzymol. 2000;314:506-24. doi: 10.1016/s0076-6879(99)14126-0. Methods Enzymol. 2000. PMID: 10565036 No abstract available.

9

Problems associated with oligonucleotide radiotherapy.

Kairemo KJ, Jekunen AP, Tenhunen M. Kairemo KJ, et al. Among authors: tenhunen m. J Nucl Med. 1999 Sep;40(9):1582. J Nucl Med. 1999. PMID: 10492382 Free article. No abstract available.

10

Accuracy requirements for head and neck intensity-modulated radiation therapy based on observed dose response of the major salivary glands.

Kapanen M, Collan J, Saarilahti K, Heikkonen J, Kairemo K, Tenhunen M. Kapanen M, et al. Among authors: tenhunen m. Radiother Oncol. 2009 Oct;93(1):109-14. doi: 10.1016/j.radonc.2009.04.023. Epub 2009 May 10. Radiother Oncol. 2009. PMID: 19435641

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

152 results

Search Page

Filters